MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05304nam a22006137a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220222s20222022 xxu||||| |||| 00| 0 eng d |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1001/jamanetworkopen.2021.48172 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
2789004 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
35157055 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. |
| 251 ## - Source |
|---|
| Source |
JAMA Network Open. 5(2):e2148172, 2022 02 01. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
JAMA netw. open. 5(2):e2148172, 2022 02 01. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
JAMA netw. open. 5(2):e2148172, 2022 02 01. |
| 253 ## - Journal Name |
|---|
| Journal name |
JAMA network open |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2022 02 01 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2022-02-22 |
| 268 ## - Previous citation |
|---|
| -- |
JAMA Network Open. 5(2):e2148172, 2022 02 01. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Conclusions and Relevance: This study suggests that, both in-trial and over the lifetime, IPE offers better cardiovascular outcomes than standard care in REDUCE-IT participants at common willingness-to-pay thresholds. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Design, Setting, and Participants: An in-trial cost-effectiveness analysis was performed using patient-level study data from REDUCE-IT, and a lifetime analysis was performed using a microsimulation model and data from published literature. The study included 8179 patients with hypertriglyceridemia despite stable statin therapy recruited between November 21, 2011, and May 31, 2018. Analyses were performed from a US health care sector perspective. Statistical analysis was performed from March 1, 2018, to October 31, 2021. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Importance: The Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT) demonstrated the efficacy of icosapent ethyl (IPE) for high-risk patients with hypertriglyceridemia and known cardiovascular disease or diabetes and at least 1 other risk factor who were treated with statins. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Interventions: Patients were randomly assigned to IPE, 4 g/d, or placebo and were followed up for a median of 4.9 years (IQR, 3.5-5.3 years). The cost of IPE was |
| -- |
.16 per day after rebates using SSR Health net cost (SSR cost) and |
| -- |
.28 per day with wholesale acquisition cost (WAC). |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Main Outcomes and Measures: Main outcomes were incremental quality-adjusted life-years (QALYs), total direct health care costs (2019 US dollars), and cost-effectiveness. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Objective: To estimate the cost-effectiveness of IPE compared with standard care for high-risk patients with hypertriglyceridemia despite statin treatment. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Results: A total of 4089 patients (2927 men [71.6%]; median age, 64.0 years [IQR, 57.0-69.0 years]) were randomly assigned to receive IPE, and 4090 patients (2895 men [70.8%]; median age, 64.0 years [IQR, 57.0-69.0 years]) were randomly assigned to receive standard care. Treatment with IPE yielded more QALYs than standard care both in trial (3.34 vs 3.27; mean difference, 0.07 [95% CI, 0.01-0.12]) and over a lifetime projection (10.59 vs 10.35; mean difference, 0.24 [95% CI, 0.15-0.33]). In-trial, total health care costs were higher with IPE using either SSR cost ( |
| -- |
8786) or WAC ( |
| Source |
4544) than with standard care ( |
| -- |
7273; mean difference from SSR cost, |
| -- |
513 [95% CI, |
| -- |
55- |
| Source |
870]; mean difference from WAC, |
| -- |
271 [95% CI, |
| -- |
911- |
| Field link and sequence number |
630]). Icosapent ethyl cost |
| Source |
2311 per QALY gained using SSR cost and |
| -- |
07218 per QALY gained using WAC. Over a lifetime, IPE was projected to be cost saving when using SSR cost ( |
| -- |
95276) compared with standard care ( |
| -- |
97064; mean difference, - |
| -- |
788 [95% CI, - |
| -- |
735 to |
| Linkage |
159]) but to have higher costs when using WAC ( |
| Source |
02830) compared with standard care (mean difference, |
| -- |
766 [95% CI, |
| -- |
094- |
| -- |
0438]). Compared with standard care, IPE had a 58.4% lifetime probability of costing less and being more effective when using SSR cost and an 89.4% probability of costing less than |
| -- |
0000 per QALY gained when using SSR cost and a 72.5% probability of costing less than |
| -- |
0000 per QALY gained when using WAC. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Cost-Benefit Analysis |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Eicosapentaenoic Acid/ec [Economics] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Eicosapentaenoic Acid/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hydroxymethylglutaryl-CoA Reductase Inhibitors/ec [Economics] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hyperlipidemias/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hyperlipidemias/ec [Economics] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Eicosapentaenoic Acid/aa [Analogs & Derivatives] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Risk Factors |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Health Research Institute |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Heart & Vascular Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Research Support, Non-U.S. Gov't |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Dolman, Sarahfaye |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Kolm, Paul |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Weintraub, William S |
| 790 ## - Authors |
|---|
| All authors |
Andrade K, Ballantyne CM, Bellows BK, Bhatt DL, Boden WE, Bress AP, Brinton EA, Derington CG, Dolman S, Jacobson TA, Johnson J, King JB, Kolm P, Miller M, Steg PG, Tajeu GS, Tardif JC, Weintraub WS, Zhang Z |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1001/jamanetworkopen.2021.48172">https://dx.doi.org/10.1001/jamanetworkopen.2021.48172</a> |
| Public note |
https://dx.doi.org/10.1001/jamanetworkopen.2021.48172 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
